FDA’s OPDP untitled letters show rising scrutiny of DTC ads’ overall impression on consumers and urge companies to balance ...
Letters: Political ad gets it wrong on Acton. What about Trump's macrolooting?
The US Food and Drug Administration (FDA) has published scores of warning letters, most of them to companies for marketing and advertising compounded versions of glucagon-like peptide-1 (GLP-1) ...
Given the copious rules and regulations placed on pharma DTC ads, it’s no wonder tropes abound in the space. And tropes, of course, make things easy to spoof. (Who can forget the faux-warning, “May ...
The FDA’s Office of Prescription Drug Promotion issued an Untitled Letter, backdated to September 23, to Tracey M. Henderson, MS, MBA – AstraZeneca’s promotional regulatory affairs review director, ...
The US Food and Drug Administration (FDA) Office of Prescription Drug Promotion (OPDP) has issued its first two untitled letters of the year to two companies, Altor BioScience and BeOne Medicines ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results